Ocular Therapeutix: chief scientific officer Jeffrey S. Heier sold 10,869 shares

What happened Jeffrey S. Heier, chief scientific officer, sold 10,869 shares in an open market or private sale on Oct 2, 2026. The filing reports a weighted average sale price of $7.05 for total proceeds of $76,626.

Key details

• Transaction date and price: Oct 2, 2026; weighted average price $7.05; individual sale prices ranged from $6.9900 to $7.2100.
• Shares owned after the transaction: the filing does not report shares owned after the transaction.
• Footnotes: (F1) Sales were made pursuant to a durable automatic sale instruction adopted Apr 9, 2024, as a sell-to-cover election to satisfy tax withholding for restricted stock units that vested on Oct 1, 2026; the filing states the sales were not a discretionary trade. (F2) The reported price is a weighted average; the reporting person offers to provide a breakdown of the number of shares sold at each price on request.
• Filing date and reporting period: Form 4 filed Oct 6, 2026, reporting the Oct 2, 2026 transaction.

Why it may matter The filing indicates the shares were sold under an automatic sell-to-cover instruction to meet tax withholding related to RSU vesting, and states the sales were not discretionary. The filing does not show why the insider traded or why the company acted.